Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345637 | 1.00 | RAB9A (0.82) | RAB9ALMNATP53GAAKDM4E | |
| SCHEMBL22345636 | 1.00 | RAB9A (0.82) | RAB9ALMNATP53GAAKDM4E | |
| SCHEMBL12468462 | 0.90 | RAB9A (1.00) | RAB9ALMNATP53GAAKDM4E | |
| SCHEMBL22345781 | 0.85 | RAB9A (0.76) | RAB9ALMNATP53GAAKDM4E | |
| SCHEMBL22345779 | 0.85 | RAB9A (0.76) | RAB9ALMNATP53GAAKDM4E | |
| SCHEMBL24494781 | 0.80 | RAB9A (0.54) | RAB9ALMNA | |
| SCHEMBL24494768 | 0.80 | RAB9A (0.54) | RAB9ALMNA | |
| SCHEMBL22360519 | 0.80 | RAB9A (0.54) | RAB9ALMNA | |
| SCHEMBL14673041 | 0.78 | RAB9A (0.66) | RAB9ALMNATP53GAAKDM4E | |
| SCHEMBL28280294 | 0.78 | RAB9A (0.50) | RAB9ALMNATP53GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4248960-A2 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2023-09-27 | — | — | EP | disclosed |
| EP-3924361-B1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LTD (IN) | 2023-09-06 | — | — | EP | disclosed |
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2022-06-09 | — | — | US | disclosed |
| EP-3924361-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | Hetero Labs Limited (IN) | 2021-12-22 | — | — | EP | disclosed |
| WO-2020165741-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2020-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177439-A1 | NOVEL TRITERPENE DERIVATIVES AS HIV INHIBITORS | CYP51A1, CCR5, HSD17B7 | RAB9A 1409/4885LMNA 4342/4885TP53 2879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.